Brief: Candel Therapeutics Announces New Data From Ongoing Phase 1 Clinical Trial Of CAN-3110
19/05/2023 14:46
May 19 (Reuters) - Candel Therapeutics Inc CADL.O :
* CANDEL THERAPEUTICS ANNOUNCES NEW DATA FROM ONGOING PHASE
1
CLINICAL TRIAL OF CAN-3110 IN RECURRENT HIGH-GRADE GLIOMA AT THE
AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) 26TH ANNUAL
MEETING
* CANDEL THERAPEUTICS INC - CAN-3110 WAS REPORTED TO BE WELL
TOLERATED WITH NO DOSE-LIMITING TOXICITIES OBSERVED
* CANDEL THERAPEUTICS - TREATMENT WITH CAN-3110 IN ARM A
SHOWED
ENCOURAGING MEDIAN OVERALL SURVIVAL RATE AT 11.8 MONTHS AFTER A
SINGLE INJECTION
Source text for Eikon: ID:nGNX7vnsKZ
Further company coverage: CADL.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec